Previous 10 | Next 10 |
Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.94 and the consensus Revenue Estimate is $4.04M Over the last 3 months, EPS estimates have seen 2 upward revisions and 7 downward. ...
ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...
Live Conference Call and Webcast at 8:30 a.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoi...
Patients who Achieved Sustained Expanded Disability Status Scale (EDSS) Improvement at any Time Showed Significant Increase in Magnetization Transfer Ratio (MTR) from Baseline at 12 Months, Suggestive of Remyelination 7 of 8 Patients Achieving Sustained Disability Improvement ...
Pierre Fabre to Commercialize Tab-cel ® for Epstein-Barr Virus (EBV)-Positive Cancers in Europe, Middle East, Africa, and Other Select Emerging Markets Atara to Receive Upfront Payment of USD 45 Million, and Up to Approximately USD 320 Million in Total Milestones, Plu...
New Magnetization Transfer Ratio (MTR) Imaging Biomarker Data and Two-Year Clinical Data from Open-Label Extension (OLE) Patients Achieving Sustained Expanded Disability Status Scale (EDSS) Improvement Show Increase in MTR at 12 Months Which May Suggest Remyelination C...
Designation recognizes therapeutic innovation and potential to address significant unmet patient need Atara on track to submit MAA in November 2021 Phase 3 ALLELE study analysis supporting tab-cel MAA to be presented in Q4 2021 Atara Biotherapeutics, Inc. ...
We take our second look at Atara Biotherapeutics and update our investment thesis to account for recent events. The company has a full slate of milestones over the next year including a rolling BLA submission. A full investment analysis and recommendation follows in the paragraphs...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive...
Seth Klarman’s 13F portfolio value decreased from $12.56B to $12.33B this quarter. Baupost Group increased Micron Technology and Facebook while dropping Fox Corp. The portfolio continues to be heavily concentrated with the top three positions accounting for ~32% of the 13F ...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...